News

Lonza that supplies an active ingredient of Increlex (mecasermin [rDNA origin] Injection) is at present working with FDA to address these issues. The interruption in the supply is

Certified by NextDocs, a provider of Microsoft SharePoint-based compliance solutions, the solution was designed to meet the challenges of migrating content in a format that meets industry and

The settlement agreement also resolves outstanding litigation against legacy Watson’s abbreviated new drug application that remains pending at FDA. Actavis president and CEO Paul Bisaro said, "The launch

According to the deal, Daiichi will support and co-sponsor a Phase 1 study assessing the effectiveness of PER977 in reversing the anticoagulant activity of its investigational oral, once-daily,

The approval allows Star Scientific to use HFL’s "Informed-Sport" and "Informed-Choice" trademarks on Registered Products, assuring products have been tested for substances prohibited in sport. HFL will test

The Aegis5-14 Film, which is built on the CX5-14 platform, has been tested for use in bioprocessing applications. Thermo Fisher marketing global director for cell culture and bioprocessing

An antibody fragment KB001A is developed against Pa that causes pneumonia in mechanically-ventilated patients. Sanofi Pasteur research and development senior vice president Michel DeWilde said, "Sanofi Pasteur is

UMEC/VI combines a long-acting muscarinic antagonist (LAMA) GSK573719 or umeclidinium bromide and a long-acting beta2 agonist (LABA) vilanterol (VI), administered using the Ellipta inhaler. The investigational once-daily LAMA/LABA

Patients will be randomised in 2:1 ratio with either 200mg of GLPG0974 two times each day or placebo for a period of four weeks. The recruitment will be